| PLH (n = 84) | PL (n = 86) | p-valuec | p-valued |
---|
RECIST version 1.1 | mRECIST | RECIST version 1.1 | mRECIST |
---|
ORRa, n (%) | 39 (46.4) | 50 (59.5) | 26 (30.2) | 36 (41.9) | 0.030 | 0.022 |
95% CI | 29.3–54.6 | 42.7–58.7 | 22.5–44.7 | 33.7–57.1 |  |  |
Overall responseb, n (%) | Â | Â | Â | Â |
CR | 5 (6.0) | 13 (15.5) | 1 (1.2) | 8 (9.3) | 0.092 | 0.223 |
PR | 34 (40.5) | 37 (44.0) | 25 (29.1) | 28 (32.6) | 0.119 | 0.124 |
SD | 37 (44.0) | 24 (28.6) | 46 (53.5) | 35 (40.7) | 0.220 | 0.098 |
PD | 7 (8.3) | 9 (10.7) | 11 (12.7) | 12 (13.9) | 0.346 | 0.522 |
NA | 1 (1.2) | 1 (1.2) | 3 (3.5) | 3 (3.5) | 0.319 | 0.319 |
- NOTE. RECIST version 1.1 or mRECIST was assessed per independent imaging review
- adefined as the proportion of individuals who had a confirmed CR or PR per independent imaging review; binvolved evaluation of the change in tumour burden inside and outside the liver; cthe comparison between the two groups is based on the RECIST version 1.1; d the comparison between the two groups is based on the mRECIST
- PLH pembrolizumab plus lenvatinib plus hepatic arterial infusion chemotherapy; PL pembrolizumab plus lenvatinib; RECIST version 1.1 Response Evaluation Criteria in Solid Tumours version 1.1; mRECIST modified RECIST; ORR objective response rate; CI confidence interval; CR complete response; PR partial response; SD stable disease; PD progressive disease; NA not assessable